MedPath

ADHERA THERAPEUTICS, INC.

ADHERA THERAPEUTICS, INC. logo
🇺🇸United States
Ownership
Public
Established
1983-01-01
Employees
1
Market Cap
-
Website
http://www.adherathera.com

Phase II Trial of Niraparib-Dostarlimab Combination Fails to Meet Primary Endpoint in Recurrent Head and Neck Cancer

A phase II trial evaluating niraparib and dostarlimab combination therapy in recurrent/metastatic head and neck squamous cell carcinoma was terminated early for futility after achieving only 20% clinical benefit versus the target of 50%.

© Copyright 2025. All Rights Reserved by MedPath